A positive bronchodilator response is found in most patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD), although its presence varies over time within the same patient as well as across patients depending, in part, on the severity of the pre-bronchodilator level of airflow obstruction. Consequently, the response to a bronchodilator does not reliably distinguish COPD from asthma, although a particularly marked response suggests the presence of asthma/COPD overlap. The absence of an acute response to a bronchodilator in COPD does not preclude a favourable long-term response to maintenance bronchodilator therapy, although it may predict a reduced magnitude of the long-term response. Bronchodilator responsiveness does not appear to define a distinct phenotype of COPD or predict most clinically meaningful outcomes. However, performing spirometry after a bronchodilator may have practical utility in clinical practice as an indicator of the maximum ("ceiling") lung function that patients are capable of attaining as a goal to attempt to achieve with pharmacotherapy. ( 
INTRODUCTION
The question whether the response to a bronchodilator matters with regard to chronic obstructive pulmonary disease (COPD) depends somewhat on whether the response is being considered as important for the following: 1) diagnosing COPD; 2) differentiating COPD from asthma or identifying an overlap of asthma with COPD (ACO); 3) assessing the severity of COPD; 4) examining the course of COPD in population-based and interventional studies; 5) predicting the long-term effectiveness of treatment based on an initial assessment of shortterm bronchodilator responsiveness; and/or 6) classifying COPD patients into a distinct phenotype that has implications with regard to predicting meaningful clinical outcomes. This article builds on previous reviews of bronchodilator reversibility in COPD 1,2 by focusing specifically on the question whether the response to a bronchodilator matters.
DEFINITION OF A "POSITIVE" BRONCHODILATOR RESPONSE AND FACTORS AFFECTING ITS DETECTION
Before addressing each of the aforementioned considerations, it is important first to define what is meant by a "positive", "meaningful" or "significant" bronchodilator response, as well as the limitations of this definition. According to the American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force on Standardization of Lung Function Testing, the response to a bronchodilator is considered positive if either the forced expiratory volume in one second (FEV 1 ) and/or the forced vital capacity (FVC) increases by ≥ 12% and/or ≥ 200 ml compared to the pre-bronchodilator value 3 . Although a positive bronchodilator response has also been defined by a 15% increase over the pre-bronchodilator FEV 1 independent of a volume increase of 200 ml, the ATS/ERS definition has the advantage of including an absolute volume threshold since patients with more severe disease may meet the 15% increase threshold due to a "low denominator" effect, while failing to meet the absolute volume threshold. Regardless of the definition used, however, it is well recognised that the bronchodilator response of an individual patient can vary depending on the dose of the bronchodilator used, the class of bronchodilator (beta 2 -agonist versus muscarinic antagonist), the method of delivery (pressurised metered dose inhaler [pMDI] with or without a spacer or a nebulizer) and the time interval between administration of the inhaled bronchodilator and performance of post-bronchodilator spirometry 4 . While administration of four separate inhalations of a short-acting beta 2 -agonist (e.g., salbutamol 100 mcg per actuation) has been recommended 3 , lower doses are often used in practice. Moreover, although a 15-minute delay between administration of the bronchodilator and performance of the post-bronchodilator spirometry has also been recommended 3 , the peak bronchodilator response may not be achieved until as long as 1-2 hours after the bronchodilator is inhaled 4 . It has also been shown that the response to a bronchodilator in individual patients varies considerably over time 1, 5 . For example, in one study 52% of patients who initially did not exhibit a positive response (defined by a 10% predicted improvement in FEV 1 ) changed their responsiveness (from negative to positive responses or vice versa) on repeated testing on different days 1 (Fig. 1) . In the more recent observational study Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) of 1831 patients with COPD in whom reversibility was assessed 15 min after administration of 400 µg salbutamol on four separate occasions, only 16% of subjects who were reversible at the first visit met reversibility criteria on all follow-up visits, while 66% who were irreversible initially remained irreversible at all subsequent visits 5 .
Likely reasons for this variability in responder status over time include the between-test variability in the FEV 1 measurement itself, the between-day variation in bronchomotor tone and the only small change that is sometimes required to move between response categories. Another source of variation in evaluating responsiveness is the class or classes of bronchodilator used (beta 2 -agonist, muscarinic antagonist or both combined) 6, 7 . Some COPD patients appear to respond preferentially to a short-acting beta 2 -agonist, while others to a short-acting muscarinic antagonist 6 . Pharmacogenetic data from Japan suggest that the preferential response to the two different classes of short-acting bronchodilators may be determined by beta 2 -adrenergic polymorphisms 8 . An additional source of variation in bronchodilator responsiveness is the baseline severity of airflow obstruction. For example, the flow response (FEV 1 ) has been shown to be generally poor in patients with mild-to-moderate airflow obstruction 9 , greatest in those with moderate obstruction 10, 11 (Table 1 ) and progressively smaller with increasing severity of obstruction. In contrast, the volume response appears to be somewhat equivalent across different grades of severity from moderate-to-very-severe, such that the most severely obstructed patients (i.e., those most likely to be hyperinflated 12 ) tend to be predominantly volume responders while only moderately obstructed patients tend to be predominantly flow responders 10 (Table 1) . In this regard, in studies reporting the proportion of COPD patients who respond positively to a bronchodilator, primary emphasis is usually placed on the flow response and the volume response is often ignored. This is unfortunate since a positive volume response implies reductions in gas trapping and lung hyperinflation, features that contribute at least as importantly to exercise limitation and exertional dyspnoea as airflow obstruction 13 .
DIAGNOSING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A defining feature of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) is the presence of airflow obstruction that is "not fully reversible", i.e., only "partially" reversible, in response to a bronchodilator 14 [20] [21] [22] [23] [24] . Moreover, using data from the Lung Health Study (LHS), Mannino et al. 25 have shown that both pre-and post-bronchodilator lung function predicted mortality with similar accuracy; however, all LHS patients had to have a reduced post-bronchodilator FEV 1 /FVC to be eligible to participate in the study. Interestingly, 8.5% of Genetic epidemiology of COPD (COPDGene) subjects had a reduced pre-but normal post-bronchodilator FEV 1 /FVC ratio and 3% of the subjects had a normal pre-but reduced post-bronchodilator ratio, largely due to a post-bronchodilator increase in FVC 26 . Interestingly, however, obstruction defined by either or both pre-and post-bronchodilator ratios showed similar associations with symptoms of chronic bronchitis and dyspnoea, reduced exercise capacity and percentage of emphysema and gas trapping on high-resolution computed tomography (HRCT), suggesting a similar burden of disease irrespective of the bronchodilator response in this subject population. On the other hand, obstruction on both pre-and post-bronchodilator spirometry showed a stronger association with exacerbations than obstruction on the post-or pre-bronchodilator test alone and only post-bronchodilator obstruction was associated with increased mortality 26 .
In view of the above considerations, it is not entirely clear to what extent defining COPD by the pre-versus post-bronchodilator FEV 1 /FVC ratio truly matters. What complicates this debate even further is the finding that many current and former cigarette smokers with preserved spirometry, namely a normal pre-bronchodilator FEV 1 /FVC ratio, have chronic respiratory symptoms according to the COPD Assessment Test (CAT) compared with non-smokers and that these individuals have COPD-like findings on HRCT (gas trapping and/or visual evidence of emphysema), are often prescribed medication for COPD and develop exacerbations and acute worsening of symptoms requiring additional medication [27] [28] [29] [30] . It is likely that these individuals may proceed to develop overt COPD as defined spirometrically.
DIFFERENTIATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ASTHMA/CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP
Historically, COPD was considered to be characterised by irreversible airflow obstruction, as distinguished from asthma in which reversible bronchospasm or increased airways reactivity in response to bronchoconstrictor stimuli is a defining feature. Because of this perception, bronchodilator responsiveness has been suggested as a feature that might distinguish between asthma and COPD 31 . On the other hand, several studies have demonstrated that a large proportion of patients with COPD without features suggestive of asthma other than responsiveness to a bronchodilator exhibit a positive response to a bronchodilator (or combination of bronchodilators) 7, 10 . As a consequence of these findings, a component of the current characterisation of COPD is the frequent presence of "partially" or "not fully" reversible airflow obstruction while the relevance of the response to a bronchodilator as a means of distinguishing between asthma and COPD has been downplayed. In addition, 16-25% and 33-43% of patients with well-established mild-to-moderate or moderate-to-severe asthma, respectively, have been shown to have a "fixed" component of airflow obstruction defined by an FEV 1 /FVC ratio < LLN or < 0.70 that fails to improve above the LLN or above 0.70 in response to a bronchodilator 32, 33 , at least when tested on a single occasion. With therapy including inhaled glucocorticoids (ICS), full reversibility is restored in some, but not all, of these patients 34 .
The increasing recognition that some patients with COPD or asthma have features of both diseases has led to the characterisation of these patients as having ACO, or asthma-COPD overlap 35, 36 . Although some have characterised this condition as a syndrome, others argue that ACO, like COPD and asthma alone, is a heterogeneous spectrum of disorders with varying phenotypic features and underlying pathophysiology and discourage applying the term "syndrome". Although there is no real consensus regarding a definition of ACO, different groups have proposed diagnostic criteria [37] [38] [39] [40] .
A minor criterion in most of the proposed definitions is the presence of significant bronchodilator reversibility (≥ 12% and ≥ 200 ml increase in FEV 1 ) on 2 or more occasions and a major criterion is the presence of marked reversibility with bronchodilators (≥ 15% and ≥ 400 ml increase in FEV 1 ) [34] [35] [36] [37] . A problem with the proposed minor criterion is that patients with well-defined COPD frequently exhibit this level of bronchodilator reversibility on ≥ 2 occasions 1,6,7 , while marked reversibility (the major criterion) is distinctly uncommon in COPD. In the Understanding Potential Longterm Impacts on Function with Tiotropium (UPLIFT) trial, however, about 15% of patients exhibited this marked response 10 (Fig. 2) , but this response was to high doses of two different classes of bronchodilators with timing of the post-bronchodilator spirometry to match the expected peak action of each bronchodilator class 41 . Of course, it is also possible that the 15% of the UPLIFT patients who exhibited a particularly marked bronchodilator response might have had ACO. Interestingly, according to a systematic literature review of ACO in patients with COPD, the reported prevalence has varied from 12.1% to 55.2% 42 , most likely reflecting varying diagnostic criteria for both COPD and ACO and varying population characteristics, such as age, sex and smoking. A currently unmet need is to obtain a better understanding of the clinical, phenotypic and endotypic characteristics of ACO, including its prevalence, natural history, pathophysiology and response to treatment. Since existing studies of treatment responses in COPD and in asthma exclude patients with features of both diseases, no information is currently available concerning optimal therapy for patients with ACO, underscoring the importance of arriving at a consensus for defining this disorder.
ASSESSING THE SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
According to the 2007 GOLD report, the severity of airflow obstruction (mild, moderate, severe and very severe) was defined by the post-bronchodilator FEV 1 percentage predicted (≥ 80%, 50-79%, 49-30% and < 30%, respectively) 43 , a definition that has been applied to entry criteria for clinical trials in which the target population comprises patients with specified degrees of spirometric severity of obstruction. In the 2011 GOLD report, the severity of airflow obstruction as thus defined was incorporated into an algorithm whereby recommendations for treatment with different classes of pharmacologic agents for patients with stable COPD were tied to a combination of respiratory symptom burden, level of obstruction and history of exacerbations 44 . This treatment algorithm was modified in the 2017 report to eliminate severity of airflow obstruction since the latter has been shown to be poorly correlated with symptoms, exercise tolerance and health-related quality of life, so that the only remaining features guiding recommended therapeutic options are symptom level and exacerbation risk 14 . On the other hand, in a small single-centre study of 300 consecutively seen Taiwanese patients with COPD, severity defined by the postbronchodilator FEV 1 percentage predicted was an independent predictor of mortality in multivariate analysis, whereas pre-bronchodilator FEV 1 predicted was not 45 . Moreover, the postbronchodilator percentage predicted FEV 1 was more strongly correlated than the pre-bronchodilator value with all other studied outcome predictors, including body mass index (BMI), modified Medical Research Council (mMRC) scale, performance status (using the Eastern Cooperative Oncology Group [ECOG] questionnaire) and hospitalisation for an acute COPD exacerbation 45 . Further studies comparing the degree of severity of airflow obstruction defined by the pre-versus post-bronchodilator percent predicted FEV 1 as a predictor of outcomes in COPD are warranted.
EXAMINING THE COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN OBSERVATIONAL AND INTERVENTIONAL STUDIES
Numerous observational and interventional studies have measured the annual rate of change in FEV 1 as a marker of COPD progression. In contrast to most previous observational studies, the landmark Lung Health Study I, in which the impact of early intervention on the annual rate of decline in FEV 1 was investigated in smokers with mild-to-moderate airflow obstruction over a 5-year period, chose the post-bronchodilator FEV 1 over the pre-bronchodilator value to chart the course of lung function decline 47 . Subsequent intervention trials of potentially disease-modifying therapy over the ensuing 25 years have also utilis ed the post-, rather than the pre-, bronchodilator FEV 1 to delineate the progression of COPD [48] [49] [50] [51] [52] [53] [54] [55] . The rationale for the choice of the post-over the pre-bronchodilator FEV 1 for this purpose has not been clearly articulated but may have derived from the belief that the post-may be less variable than the pre-bronchodilator FEV 1 or that it would be less influenced by failure to adhere to instructions to withhold any bronchodilator medication during the prescribed washout period prior to spirometric testing. However, using data from 4484 participants in the Lung Health Study with pre-and post-bronchodilator measurements we showed that the variability of Figure 2 . Proportion of patients (n = 5656) showing absolute changes (ml) in pre-to post-bronchodilator forced expiratory volume in one second (FEV 1 ) (reproduced with permission from Tashkin DP et al. 10 ). ¶ 55% showed a ≥ 200 ml increase in FEV1; approximately 15% showed a ≥ 400 ml increase in FEV 1 .
the mean FEV 1 at each annual visit was slightly greater for the post-than the pre-bronchodilator value, while estimates for the slope of FEV 1 decline using a random coefficient model that included time, sex, age, BMI, methacholine reactivity and baseline smoking intensity were similar 56 . These findings imply that serial measurements of the pre-bronchodilator FEV 1 are generally adequate for comparing the effect of different interventions on the trajectory of FEV 1 over time at least in COPD subjects with mild-to-moderate airflow obstruction.
On the other hand, in patients with moderate-to-very severe airflow obstruction participating in the 4-year UPLIFT trial, the slope of the post-bronchodilator FEV 1 (estimated using a linear mixed effects model that adjusted for height, sex, smoking status, baseline percentage predicted FEV 1 and baseline bronchodilator response) was significantly steeper than the pre-bronchodilator slope regardless of treatment arm (tiotropium versus placebo) 57 (Fig. 3) , while the estimated variances of the pre-and post-bronchodilator slopes were similar. These slope differences need to be taken into consideration in evaluating the impact of an intervention on the annual rate of change in FEV 1 in response to an intervention since the effect of the intervention might vary depending on whether the change was defined by the pre-versus the post-bronchodilator measurement.
If the acute response to a bronchodilator declined over time, this could possibly explain the steeper post-versus pre-bronchodilator slope of FEV 1 observed in the UPLIFT study. In support of this hypothesis, further analysis of data from this long-term trial revealed progressive and highly significant mean declines in the FEV 1 (as well as the FVC) response to bronchodilator administration as the subjects aged (p < 0.0001) 58 (Fig. 4) . Similar findings had been observed in the Clinical Study of Intermittent Positive Pressure Breathing (IPPB) when the bronchodilator response was reported as change in the percentage predicted FEV 1 59 . In the UPLIFT trial participants, moreover, the declines in both the FEV 1 and FVC bronchodilator responses were generally larger in patients with severe-to-very severe (GOLD grades 3/4) than mild-to-moderate (GOLD grades 1/2) airflow obstruction, in older patients (> 65 years of age) and in former compared to current smokers 57 . The observed declines in bronchodilator responsiveness over time parallel the usually progressive age-related decline in lung function that is typical of COPD 14, 46, 60 , suggesting an inter-relationship between these two phenomena. Although speculative, a possible mechanism contributing to these age-related declines in the FEV 1 response to a bronchodilator is the progressively increased thickness of the walls of the small airways with increasing severity of airflow obstruction, as demonstrated by Hogg et al. 61 . Since the increasing wall thickness with decreasing FEV 1 is likely to be accompanied by a decrease in airway wall compliance, this effect would be to attenuate the increase in airway luminal patency (and thus in FEV 1 ) in response to bronchodilator-induced airway smooth muscle relaxation.
Another possible explanatory mechanism for the diminution of both FEV 1 and FVC responses to a bronchodilator with age is the loss of lung elasticity with age 62 that is likely to increase dynamic airway compression, thereby counteracting drug-induced bronchodilation and reduction in gas trapping. Regardless of the underlying mechanism, from a clinical perspective the declines in bronchodilator responsiveness with aging might result in a general loss of clinical efficacy of bronchodilator therapy over time.
PREDICTING THE LONG-TERM EFFECTIVENESS OF MAINTENANCE BRONCHODILATOR TREATMENT BASED ON AN INITIAL ASSESSMENT OF SHORT-TERM BRONCHODILATOR RESPONSIVENESS
Several older studies have suggested that the acute or initial response to a short-or long-acting bronchodilator may not be predictive of the long-term response to a long-acting bronchodilator 63, 66 . For example, Mahler and al. 63 studied the 12-hour FEV 1 responses over 12 weeks to salmeterol bid, ipratropium qid and placebo in 411 COPD patients with moderate-to-very-severe airflow obstruction stratified by positive or negative bronchodilator reversibility categories based on their screening response to albuterol, a positive responder status being defined as an increase in FEV 1 of ≥ 12% and ≥ 200 ml over the pre-bronchodilator value 30 minutes after administration of 180 µg albuterol 63 . Although the 12-week FEV 1 responses to both salmeterol and ipratropium compared to placebo were significantly higher in the positive responder than the non-responder group, they were still significantly higher versus placebo in the non-responder group, and the FEV 1 responses to both active agents over placebo were noticeably higher on the last study day (12 weeks) compared to the day of randomisation.
Similar results were obtained by Rennard et al. 64 in 405 patients in a similarly designed study in which the responders had a greater benefit from salmeterol than the non-responders, but the non-responders also exhibited a significant benefit compared to placebo, albeit of lesser magnitude compared to that experienced by the responders. Post-hoc analysis of data from two one-year randomised controlled trials of the long-acting muscarinic antagonist, tiotropium, versus placebo in 921 patients with moderate-to-very-severe COPD was performed to determine whether long-term improvements in lung function and health-related quality of life were associated with short-term improvements in FEV 1 measured on the first day of the study 66 . Patients assigned to tiotropium were stratified for purposes of analysis into good responders and poor responders to tiotropium on the first study day, good responders being defined as those who exhibited a ≥ 12% and ≥ 200 ml improvement in FEV 1 compared to baseline within 120 minutes after the initial dose of tiotropium. Both the good responders and poor responders to tiotropium on the first day of the trial showed significant 1-year improvements not only in FEV 1 , but also in reduction in rescue inhaler use, dyspnoea (Transition Dyspnoea Index [TDI]) and healthrelated quality of life ([HRQoL] St. George's Respiratory Questionnaire), compared to patients in the placebo arm. However, the magnitude of improvements after one year was greater in the first-day tiotropium responders than the poor tiotropium responders (Fig. 5) . These findings complement those using a longacting beta-agonist and imply that the shortterm response to either a rapid-acting or longacting bronchodilator should not be used as a criterion for prescribing long-term bronchodilator treatment.
DOES BRONCHODILATOR RESPONSIVENESS DEFINE A DISTINCT PHENOTYPE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE?
A COPD phenotype is defined by observable features that distinguish subgroups of patients from other subgroups in relation to clinically meaningful outcomes. A problematic challenge in addressing the question whether bronchodilator responsiveness defines a distinct COPD phenotype arises from the fact that significant responsiveness to a bronchodilator in any given patient with COPD (i.e., an improvement of ≥ 12% and ≥ 200 ml over the pre-bronchodilator value) often changes over time 1 . Albert et al. 45 attempted to circumvent this problem by comparing the relationship of 227 consistently responsive with 1362 consistently nonresponsive patients to clinical outcomes using data from the 3-year observational study Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Using logistic regression, they failed to find any significant difference between these two reversibility subgroups with regard to mortality, hospitalisation for a COPD exacerbation or withdrawal from the study 45 . On the other hand, they did observe a significantly greater occurrence of frequent moderate to severe exacerbations (≥ 2/yr) in the non-reversible subgroup after adjusting for age, sex, smoking status and BMI. However, this difference disappeared after adjustment for the pre-bronchodilator FEV 1 percentage predicted, likely as a result of the fact that FEV 1 reversibility diminishes with increasing airflow obstruction 10, 11 , as already stated, while the proportion of frequent exacerbators increases with the severity of obstruction 67 . Figure 5 . Mean FEV 1 before and after treatment with tiotropium on days 1 and 344 of the study. For all time points following drug administration, tiotropium significantly (p < 0.001) improved lung function in both the first-day good and poor tiotropium responders, but the magnitude of the response on day 344 was substantially smaller in the poor than in the good first-day responders (reproduced with permission from Tashkin DP et al. 66 ). FEV 1 : forced expiratory volume in one second.
A related phenotypic consideration is the question whether acute bronchodilator responsiveness predicts the subsequent course of COPD as defined by the annual rate of decline in lung function. In patients with initially mild-to-moderate airflow obstruction participating in the LHS, acute bronchodilator responsiveness at baseline did not predict the subsequent decline in FEV 1 over 11 years of follow-up 68 . In the ECLIPSE cohort, as reported by Vestbo et al. 69 , those with bronchodilator reversibility at baseline had a mean rate of FEV 1 decline over 3 years that was 17.4 ml/yr greater than the mean rate of decline in the entire cohort (33 ± 2 ml/yr). However, the annual rate of decline in FEV 1 in COPD patients has been shown to be influenced by the baseline severity of airflow obstruction such that those with moderate obstruction (FEV 1 , 50-79% predicted) exhibit the most rapid decline, the rate of which decreases progressively in those with more severe obstruction 60 . Consequently, it is not unlikely that the more rapid rate of decline observed in the ECLIPSE subjects with positive reversibility was influenced by the fact that their mean baseline FEV 1 was substantially higher than that in the subgroup without reversibility at baseline. The annual decline in FEV 1 in patients with COPD is remarkably heterogeneous 68 and is influenced most strongly by smoking status 47 , as well as by airway reactivity to methacholine 70 , the degree of airflow obstruction 60 , the presence of clinically significant emphysema on thoracic HRCT 69 and the level of Clara cell protein (CC) 16 in blood [69] [70] [71] . On top of these influences, it is unlikely that the acute response to a bronchodilator has any useful prognostic utility in predicting the course of COPD as reflected by the trajectory of changes in lung function.
CONCLUSIONS
It is not entirely clear whether measuring the acute response to a bronchodilator in COPD truly matters depending on what aspect of COPD is under consideration. Defining a positive or significant bronchodilator response in accordance with the ATS/ERS recommendations is confounded by the considerable temporal variability of a positive or negative response in individual patients. While fulfilling the definition of COPD currently requires measurement of the post-bronchodilator FEV 1 /FVC ratio, it has become increasingly evident that a significant proportion of smokers without obstruction so defined have chronic respiratory symptoms and other COPD-like features. Since the majority of patients with COPD respond positively to a bronchodilator at any point in time, bronchodilator reversibility is not a reliable feature for distinguishing between asthma and COPD, unless the response is particularly marked. While the severity of airflow obstruction is defined by the post-bronchodilator FEV 1 percentage predicted in accordance with the GOLD report, this categorization is no longer taken into account in the most recent GOLD treatment algorithm recommending preferred options for treatment with different classes of drugs 14 . Although most studies of the impact of different interventions on the progression of COPD now rely on the post-rather than the pre-bronchodilator FEV 1 to track the course of the disease, use of the pre-bronchodilator FEV 1 produces slopes of decline that are not too dissimilar and also simplifies the design of population-based observational studies. The lack of a short-term response to a bronchodilator does not preclude long-term effectiveness of maintenance bronchodilator therapy, although it does predict a generally lesser magnitude of the response in the longterm. Bronchodilator responsiveness does not appear to define a distinct phenotype of COPD or predict most clinically meaningful outcomes.
While the aforementioned observations suggest that the response to a bronchodilator may not matter much, there may be some practical utility in routinely measuring lung function after a bronchodilator for comparison with previous post-bronchodilator values to obviate confounding of spirometry results by variable times since the last bronchodilator medication was used prior to testing. In addition, post-bronchodilator spirometry might be useful to estimate the maximum or "ceiling" lung function that patients are capable of attaining as a goal to strive to achieve with pharmacotherapy, as well as to obtain some sense of the expected magnitude of benefit from maintenance bronchodilator medication 62, 63, 65 . In this practical regard, measuring the response to a bronchodilator may matter.
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